Discover Zealand Pharma's Q4 2024 earning highlights, key obesity pipeline advancements, and future plans for petrelintide and dapiglutide.

Researchers have suggested that uniform evidence standards and reporting requirements could help speed patient access to cell ...

Historically, clinical trials have under-represented women and minorities. Clinical Trial Media's Cara Brant offers ...

A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage ...

Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...

Supernus Pharmaceuticals (NASDAQ:SUPN) stock drops as depression candidate SPN-820 misses main goals in Phase 2b trial. Read more here.

Objective: This study aims to investigate the drainage effect and clinical outcomes of negative pressure chest drainage in patients after two-port thoracoscopic valve surgery, comparing the ...

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS ...

A real-world study in Spain finds faster improvements with induction therapy but highlights long-term drug survival ...

Supernus (SUPN) announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically ...

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...